[
  {
    "ts": null,
    "headline": "Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.",
    "url": "https://finnhub.io/api/news?id=044017e19ebe1d50cfc430a3ff3228aa439816b10b990ee3b83059074105383b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762176600,
      "headline": "Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide",
      "id": 137302136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.",
      "url": "https://finnhub.io/api/news?id=044017e19ebe1d50cfc430a3ff3228aa439816b10b990ee3b83059074105383b"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon",
    "summary": "The healthcare industry is chock-full of opportunities for long-term investors.",
    "url": "https://finnhub.io/api/news?id=7a8c2fee40cad3661d3c0126da72574b97a99c9cdf0fe3b93a8047bc3fec6bdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762176480,
      "headline": "2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon",
      "id": 137302137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The healthcare industry is chock-full of opportunities for long-term investors.",
      "url": "https://finnhub.io/api/news?id=7a8c2fee40cad3661d3c0126da72574b97a99c9cdf0fe3b93a8047bc3fec6bdc"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: The Next Eli Lilly Might Already Be Trading Under $50",
    "summary": "Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.",
    "url": "https://finnhub.io/api/news?id=d06c9c9f6ffdc5a83e78bbfc448e285cd28f28d0a7b205369788354bf08b6791",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762163100,
      "headline": "Prediction: The Next Eli Lilly Might Already Be Trading Under $50",
      "id": 137302138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.",
      "url": "https://finnhub.io/api/news?id=d06c9c9f6ffdc5a83e78bbfc448e285cd28f28d0a7b205369788354bf08b6791"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Rise; Palantir, Robinhood Earnings Ahead",
    "summary": "The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.",
    "url": "https://finnhub.io/api/news?id=a5bde212159e83686de250a248f466f6fc17acd07ad1d3e65483e25e59f63370",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762142783,
      "headline": "Dow Jones Futures Rise; Palantir, Robinhood Earnings Ahead",
      "id": 137302139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.",
      "url": "https://finnhub.io/api/news?id=a5bde212159e83686de250a248f466f6fc17acd07ad1d3e65483e25e59f63370"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & Company (NYSE:LLY) on October 17 following the exclusion of the company’s oral GLP-1 treatment, orforglipron, from the first group of medications to […]",
    "url": "https://finnhub.io/api/news?id=6eee046d30a3f55c755726478c557878c8234f49e88df4178a5b880aff40ee20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762139449,
      "headline": "Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback",
      "id": 137302140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & Company (NYSE:LLY) on October 17 following the exclusion of the company’s oral GLP-1 treatment, orforglipron, from the first group of medications to […]",
      "url": "https://finnhub.io/api/news?id=6eee046d30a3f55c755726478c557878c8234f49e88df4178a5b880aff40ee20"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Desperate Move",
    "summary": "Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=e00805c96aa4568bd2d7d1e10b14d04a28b64bf4547df75717d12193d6d04c07",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762137971,
      "headline": "Novo Nordisk: Desperate Move",
      "id": 137300713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1128550847/image_1128550847.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=e00805c96aa4568bd2d7d1e10b14d04a28b64bf4547df75717d12193d6d04c07"
    }
  }
]